Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231633 · ClinicalTrials.gov registry record · NA
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
A NA study of Macular Edema and Central Retinal Vein Occlusion, sponsored by Long Island Vitreoretinal Consultants.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT01231633: Completed NA study of Macular Edema and Central Retinal Vein Occlusion, sponsored by Long Island Vitreoretinal Consultants.
NCT01231633 is a NA study of Macular Edema and Central Retinal Vein Occlusion that has completed, run by Long Island Vitreoretinal Consultants. The registered enrollment target is 27 participants, below the 178-participant average among 14 other Macular Edema trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01231633, a NA study of Macular Edema and Central Retinal Vein Occlusion, has completed, sponsored by Long Island Vitreoretinal Consultants.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
Primary Outcome
The change in visual acuity (number of ETDRS - Early Treatment Diabetic Retinopathy Study letters), at Month 6 as compared with baseline in each treatment arm
Conditions Studied
Interventions
- DRUG Avastin
- DRUG Ozurdex
Study Locations (4)
New York
- Long Island Vitreoretinal Consultants - Great Neck
- Long Island Vitreoretinal Consultants - Hauppauge
- Long Island Vitreoretinal Consultants - Riverhead
New Jersey
- Retina Vitreous Center - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-09 |
| Phase | NA |
What the finished NCT01231633 record still lists
NCT01231633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 178-participant average among 14 other Macular Edema trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Avastin is the first listed.
NCT01231633 reports a single indexed study location in New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01231633 about?
NCT01231633 is a clinical study titled "Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)". The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
What is the current status of trial NCT01231633?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2010-09. Estimated completion is 2014-09.
What conditions does trial NCT01231633 study?
This clinical trial studies the following conditions: Macular Edema, Central Retinal Vein Occlusion.
What interventions are being tested in trial NCT01231633?
The interventions under investigation include: Avastin (DRUG), Ozurdex (DRUG).
Who is sponsoring clinical trial NCT01231633?
This trial is sponsored by Long Island Vitreoretinal Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01231633 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01231633's enrollment target sits among peer trials
27 9th of 14 higher than 6 of 14 other Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
COMPLETED · NA
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia